CN112451509B - Chuangbuterol powder inhalation and preparation method thereof - Google Patents

Chuangbuterol powder inhalation and preparation method thereof Download PDF

Info

Publication number
CN112451509B
CN112451509B CN202011510645.1A CN202011510645A CN112451509B CN 112451509 B CN112451509 B CN 112451509B CN 202011510645 A CN202011510645 A CN 202011510645A CN 112451509 B CN112451509 B CN 112451509B
Authority
CN
China
Prior art keywords
lactose
micropowder
powder
hydrochloride
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011510645.1A
Other languages
Chinese (zh)
Other versions
CN112451509A (en
Inventor
寸冬梅
程卯生
刘婷婷
潘莉
杨明世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenyang Pharmaceutical University
Original Assignee
Shenyang Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Pharmaceutical University filed Critical Shenyang Pharmaceutical University
Priority to CN202011510645.1A priority Critical patent/CN112451509B/en
Publication of CN112451509A publication Critical patent/CN112451509A/en
Priority to PCT/CN2021/106225 priority patent/WO2022127092A1/en
Application granted granted Critical
Publication of CN112451509B publication Critical patent/CN112451509B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Abstract

The invention belongs to the field of medicinal preparations, and relates to a novel beta 2-adrenoreceptor agonist salbutamol and a powder inhalation of hydrochloride thereof, a preparation method thereof, and application of the powder inhalation in preparation of medicaments for treating asthma and chronic obstructive pulmonary disease. The invention comprises the salbutamol inhalation aerosol powder as an active ingredient and a carrier with modified surface. Wherein the weight percentage of each component is as follows: 0.05-0.25% of active ingredient, 99.75-99.95% of carrier with modified surface. The surface modified carrier is as follows: one or more of magnesium stearate, lactose or leucine micropowder is/are used as surface modifier, and one or more of lactose, mannitol or leucine is/are used as carrier. The surface modifier of the invention is added to exert the surface modification effect on the carrier, improve the aerodynamic property of the final aerosol and facilitate better deposition of drug particles in the lung. Improves the fluidity of the powder inhalation, is convenient for filling, reduces the hygroscopicity of the medicine, and is convenient for storage.

Description

Chuangbuterol powder inhalation and preparation method thereof
The technical field is as follows:
the invention belongs to the field of medicinal preparations, and relates to a novel beta 2-adrenoceptor agonist-salbutamol and a powder inhalation of hydrochloride thereof, a preparation method of the powder inhalation, and application of the powder inhalation in treatment of lung diseases such as asthma, chronic obstructive pulmonary disease and the like.
Background art:
the selective beta 2 receptor stimulant generates a bronchodilatory effect by stimulating beta 2 receptors on airway smooth muscles, and is a first-line medicament for clinically treating lung diseases such as asthma, chronic obstructive pulmonary disease and the like at present. It can rapidly improve symptoms of dyspnea and cough during acute asthma attack. The salbutamol hydrochloride is a novel high-selectivity beta 2 receptor agonist, can obviously expand airway smooth muscle, stabilize mast cells and enhance the ciliary movement capability of the airway, thereby playing the role of anti-asthma. The composition has strong antiasthmatic effect, and has effect intensity far greater than salbutamol sulfate and longer action time. In addition, compared with other similar medicines, the medicine has less adverse reaction and high safety.
Pulmonary inhalation is the first route of administration for the treatment of pulmonary diseases such as asthma. Compared with systemic administration preparations such as oral tablets and the like, the pulmonary inhalation preparation can rapidly deliver the medicine to the lung, has high medicine concentration at the action part and lower systemic exposure, thereby having quick response and effectively reducing the toxic and side effects of the whole body of the medicine. The lung inhalation preparation comprises three forms of aerosol, powder spray and water mist. A Chuangbuterol hydrochloride aerosol (CN 100431535C) was disclosed in 2008 by Jiutai pharmaceutical industry, inc., of Jinzhou, jiutai. The aerosol consists of 0.005-0.01 part of salbutamol hydrochloride, 5-10 parts of solvent and 90-95 parts of propellant. The aerosol has the disadvantage of poor stability due to the fact that the medicine is dispersed in the propellant in a dissolved or suspended state. In addition, the aerosol requires the patient to coordinate the spraying and deep-sucking actions during the use process, and has higher technical requirements, which is difficult for the old and the young patients. In addition, the development of aerosol is limited by the damage of the propellant to the ozone layer in the atmosphere in the prescription.
Dry Powder aerosols, also known as Dry Powder Inhalers (DPI), are formulations in which a Dry drug Powder or a mixed Dry Powder of a drug and an excipient is actively inhaled by the mouth of a patient into the lungs through a specific delivery device. The medicine powder is dispersed by the airflow generated by the active inhalation of the patient to form aerosol which is inhaled into a respiratory system along with the airflow to generate curative effect. The powder inhalation has the advantages of good patient compliance, simple prescription, low cost, stable medicine, environmental protection, no preservative for stimulating mucous membrane and the like. The conventional process flow of the powder cloud agent comprises the steps of crushing, mixing, filling and the like of raw material medicines. Due to the extremely small (microgram level) administration dosage of the salbutamol hydrochloride, the medicine content in the powder is easy to be uneven. In addition, the aerodynamic performance and powder flowability are also key quality attributes of the powder aerosol, and the dispersibility and the lung deposition efficiency of the powder aerosol are influenced. The aerodynamic performance of inhalation formulations is often evaluated using a Fine Particle Fraction (FPF). The problems of nonuniform content of the powder aerosol, low FPF (FPF) content, poor powder fluidity and the like are solved in the development process of the powder aerosol.
The invention content is as follows:
the invention aims to overcome the defects of the existing Chuanyterol hydrochloride preparation and provides a Chuanyterol (or Chuanyterol hydrochloride) inhalation powder inhalation and a preparation method thereof. The clenbuterol (or clenbuterol hydrochloride) inhalation powder aerosol provided by the invention has the advantages of uniform medicine content, good powder fluidity, easy dispersion and very high FPF value, is suitable for pulmonary inhalation administration, and can obtain a high pulmonary deposition rate. The invention provides a new choice with better patient compliance for treating lung diseases such as asthma, chronic obstructive pulmonary disease and the like.
The invention is realized by the following technical scheme: the Chuangbuterol powder inhalation comprises an active ingredient and a carrier subjected to surface modification. Wherein the weight percentage of each component is as follows: 0.05-0.25% of active ingredient, 99.75-99.95% of carrier with modified surface.
The active ingredient in the invention is the clenbuterol or the clenbuterol hydrochloride micro powder. The Chuanbuterol or the Chuanbuterol hydrochloride micro powder is characterized in that: wherein the median diameter (D) 50 ) Less than 2 μm,90% of the particle diameter (D) of the clenbuterol (or clenbuterol hydrochloride) micropowder 90 ) Less than 3 μm.
The surface modified carrier is a carrier surface modified by a surface modifier.
The surface modifier comprises one or more of magnesium stearate, lactose or leucine micropowder. The surface modifier is characterized in that: median diameter (D) of the surface modifier micropowder after micronization 50 ) Less than 5 mu m,90% of fine powder of carrier surface modifierParticle size (D) 90 ) Less than 10 μm.
The surface modifier is preferably the combination of lactose micropowder and magnesium stearate micropowder, and the weight ratio of the magnesium stearate micropowder to the lactose micropowder is 1:20- -1:10.
the carrier is one or more of physiologically-friendly sugar, polyalcohol and amino acid, and is selected from one or more of lactose, sucrose, glucose, fructose, maltose, trehalose, mannitol, xylitol, sorbitol, leucine, alanine, tryptophan, valine, isoleucine, glycine, phenylalanine, proline, serine, tyrosine, cysteine, methionine, glutamic acid, threonine, aspartic acid, glutamine, lysine, arginine, histidine and asparagine. The carrier is preferably one or more of lactose, mannitol or leucine. The support material is characterized in that: d 10 Greater than 10 μm, D 50 Less than 100 μm, D 90 Less than 200 μm.
The surface-modified carrier can be obtained commercially, such as lactose containing 10% lactose micropowder;
the surface-modified support may also be obtained by subjecting the surface-modifying agent to a high shear mixing treatment with the support.
Further, preferred surface-modified supports of the invention are: one or more of magnesium stearate, lactose or leucine micropowder is/are used as a surface modifier, and one or more of lactose, mannitol or leucine is/are used as a carrier. Preferred are lactose carriers containing lactose micropowder, lactose carriers containing magnesium stearate micropowder, mannitol carriers containing magnesium stearate micropowder, lactose carriers containing lactose micropowder, magnesium stearate micropowder, and the like.
The weight ratio of the carrier surface modifier to the carrier is as follows: 1:399- -25:75, preferably: 1:199- -11:39.
the invention preferably selects the following salbutamol inhalation powder inhalation, which comprises salbutamol or salbutamol hydrochloride micro powder and lactose of 10% micro powder lactose, wherein the weight percentage of each component is 1:750- -1:500. the range of the percentage of Fine Particles (FPF) of the powder spray is as follows: 25 to 35 percent.
The invention preferably selects the following salbutamol inhalation powder inhalation, which comprises salbutamol or salbutamol hydrochloride micro powder, lactose micro powder and lactose, wherein the weight percentage of each component is as follows: 1:75:675- -1:150:600. the FPF range of the powder spray is as follows: 23 to 38 percent.
The invention preferably selects the following salbutamol inhalation powder inhalation, which comprises salbutamol or salbutamol hydrochloride micro powder, magnesium stearate micro powder and lactose, wherein the weight percentage of each component is as follows: 4:15:2985- -4:45:2955. the FPF range of the powder spray is 32-43 percent.
The invention preferably selects the following salbutamol inhalation powder inhalation, which comprises salbutamol or salbutamol hydrochloride micro powder, leucine micro powder and lactose, and the weight percentage of each component is as follows: 4:15:2985- -4:45:2955. the FPF range of the powder spray is 25-32%.
The invention preferably selects the following salbutamol inhalation powder aerosol which comprises salbutamol or salbutamol hydrochloride micro powder, magnesium stearate micro powder, lactose micro powder and lactose, and the weight percentage of each component is as follows: 1:5:100:1894- -1:10:100:289. the FPF range of the powder spray is 40-51%.
The preparation method of the salbutamol or the salbutamol hydrochloride inhalation powder mist comprises the following steps:
(1) Preparing the clenbuterol or the clenbuterol hydrochloride micro powder;
(2) Preparing a surface modified carrier;
(3) The clenbuterol or the clenbuterol hydrochloride micro powder is mixed with the surface modified carrier.
The clenbuterol or the clenbuterol hydrochloride micro powder in the step (1) is prepared by adopting an air flow crushing method.
And (3) preparing the surface modified carrier in the step (2), namely performing high-shear mixing treatment on the carrier and the carrier surface modifier or the surface modifier micropowder by adopting a mixing granulator. The high shear mixing speed is 100-300rpm.
The surface modifier micro powder adopts a median diameter (D) 50 ) Less than 5 μm, D 90 Less than 10 μmThe product is available in the market, or is prepared by adopting a jet milling method.
The preparation method comprises the following steps of (1) preparing the co-pulverized micro powder of the salbutamol and the surface modifier, coarsely mixing the salbutamol or the salbutamol hydrochloride and the surface modified carrier in proportion, and preparing the mixture by adopting a co-airflow pulverization method.
The final atomized powder is obtained by mixing the salbutamol or the salbutamol hydrochloride micro powder with a surface modified carrier. The method is characterized in that the clenbuterol or the clenbuterol hydrochloride micro powder and the surface modified carrier are mixed, the clenbuterol or the clenbuterol hydrochloride micro powder and the surface modified carrier are roughly mixed by adopting an equivalent dilution method, and then the clenbuterol or the clenbuterol hydrochloride micro powder and the surface modified carrier are further mixed by adopting a high-shear mixer. The high shear mixing speed is 100-250rpm. The mixing time is 10-60min.
In the process of mixing the clenbuterol or the clenbuterol hydrochloride micro powder and the surface modified carrier, the clenbuterol or the clenbuterol hydrochloride micro powder is diluted in equal amount and then mixed, which is beneficial to improving the uniformity of the mixture.
The Chuangbuterol or the Chuangbuterol hydrochloride inhalation powder inhalation is filled by an HPMC capsule of # 3. The filling amount of the capsule is 15 mg/capsule.
The salbutamol or salbutamol hydrochloride inhalation powder aerosol has good content uniformity, and the most preferable prescription is prepared from salbutamol hydrochloride micro powder, magnesium stearate micro powder, lactose micro powder and lactose, and the components in percentage by weight are as follows: 1:5:50:445- -1:5:100:395, FPF value is more than 45%.
After the salbutamol or salbutamol hydrochloride inhalation powder inhalation is stored, the FPF value is stable. The post-storage FPF change value is less than 3%.
The salbutamol or salbutamol hydrochloride inhalation powder inhalation agent provided by the invention is a solid dry powder preparation which utilizes airflow generated by active inhalation of a patient to inhale medicine powder into the lung and exerts curative effect on the lung. The powder inhalation is characterized in that the powder inhalation of the salbutamol or the salbutamol hydrochloride inhalation powder inhalation which has uniform medicament content, low hygroscopicity, good storage stability, excellent aerodynamic property and higher FPF value and is suitable for pulmonary inhalation administration is obtained by optimizing the particle size distribution, the mixing proportion and the mixing process of the active medicament, the carrier and the carrier surface modifier in the prescription. The dry powder inhalation can be applied to capsule type, bubble cap type or storage type inhalation devices. The preparation effectively overcomes the defects of poor stability of the medicine in the aerosol, damage of the propellant to the environment, low deposition rate of the medicine in the lung, need of training a user to coordinate medicine spraying and deep inhalation actions and the like, and provides a new choice for clinical treatment of patients suffering from asthma and chronic obstructive pulmonary diseases.
The carrier is added into the powder inhalation, so that the volume and the weight of the very trace amount of the salbutamol or the salbutamol hydrochloride in the using process are increased, and the medicine is convenient to fill and use. The surface modifier is added to exert the surface modification effect on the carrier, improve the aerodynamic property of the final aerosol powder and facilitate better deposition of the drug particles in the lung. Meanwhile, the fluidity of the powder inhalation is improved, the filling is convenient, the hygroscopicity of the medicine is reduced, and the storage of the medicine is convenient.
Description of the drawings:
FIG. 1 aerodynamic results of a 100rpm mixing speed of a salbutamol powder aerosol prepared in example 1.
Figure 2 aerodynamic measurements of a salbutamol powder aerosol prepared at 250rpm mixing speed in example 2.
The aerodynamic measurement results of the salbutamol powder aerosol in the example of fig. 3.
FIG. 4 aerodynamic measurement results of an accelerated test of a 250rpm mixing speed 30min Chuanyterol powder aerosol in example 2.
Detailed Description
The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention.
Example 1
Prescription:
chuangbuterol hydrochloride 200mg
Lactose containing 10% lactose micropowder 150g
The preparation method comprises the following steps: taking the clenbuterol hydrochloride, taking compressed nitrogen as a gas source, and crushing by adopting a jet mill. Feeding pressure of 7.0bar and crushing pressure of 6.0bar, crushing, collecting to obtain the clenbuterol hydrochloride micro powder, drying and storing. The prescription dose of the clenbuterol hydrochloride micro powder and the commercial lactose carrier containing 10 percent of micro powder lactose are precisely weighed, sieved by a 60-mesh sieve, mixed, put into a wet granulator, the rotating speed is adjusted to be 100 plus or minus 10rpm, the mixing time is 10 min/time, and mixed for 6 times. After the mixing is finished, collecting the product, drying and storing. The content uniformity results are shown in table 2, which shows that the content uniformity is slightly different at different mixing times, and the aerodynamic measurement results show that the FPF value is 31.2%, and the fluidity test results show that the contact angle is 28.9 °, and the fluidity is good.
Example 2
Prescription:
chuangbuterol hydrochloride 200mg
Lactose containing 10% micropowder lactose 150g
The preparation method comprises the following steps: taking the salbutamol hydrochloride, taking compressed nitrogen as a gas source, and crushing by adopting a jet mill. Feeding pressure is 7.0bar, crushing pressure is 6.0bar, crushing is carried out, the obtained salbutamol hydrochloride micro powder is collected, and the salbutamol hydrochloride micro powder is stored under the dry condition. The clenbuterol hydrochloride micro powder with the prescription amount and the commercial lactose carrier containing 10 percent of micro powder lactose are precisely weighed, sieved by a 60-mesh sieve, mixed, put into a wet granulator, the rotating speed is adjusted to be 250 plus or minus 10rpm, the mixing time is 10 min/time, and mixed for 6 times. After the mixing is finished, collecting the product, drying and storing. The content uniformity results are shown in table 3, which shows that the content uniformity is slightly different at different mixing times, and the results of aerodynamic measurement show that the FPF value is 29.6%, and the results of fluidity test show that the contact angle is 29 °, and the fluidity is good.
Example 3
Prescription:
chuangbuterol hydrochloride 200mg
Lactose micropowder 15g
Lactose 135g
The preparation method comprises the following steps: taking the clenbuterol hydrochloride, taking compressed nitrogen as a gas source, and crushing by adopting a jet mill. Feeding pressure is 7.0bar, crushing pressure is 6.0bar, crushing is carried out, the obtained salbutamol hydrochloride micro powder is collected, and the salbutamol hydrochloride micro powder is stored under the dry condition. Precisely weighing lactose micropowder of prescription dose and lactose carrier without lactose micropowder on market, sieving with 60 mesh sieve, mixing, placing into wet granulator, adjusting rotation speed to 300 + -10 rpm, mixing for 10 min/time, and mixing for 3 times. After the mixing is finished, the modified lactose carrier containing 10% lactose micropowder is obtained and stored under the drying condition. The prescription dose of the clenbuterol hydrochloride micro powder and 150g of modified lactose containing 10% lactose micro powder are precisely weighed, the obtained product is sieved by a 60-mesh sieve, and then the obtained product is put into a wet granulator, the rotating speed is adjusted to be 250 +/-10 rpm, the mixing time is 10 min/time, and the obtained product is mixed for 3 times. After the mixing is finished, collecting the product, drying and storing. The aerodynamic measurement result shows that the FPF value is 25.1%, the fluidity test result shows that the contact angle is 28.1 degrees, and the fluidity is good.
Example 4
Prescription:
chuangbuterol hydrochloride 200mg
Lactose micropowder 30g
Lactose 120g
The preparation method comprises the following steps: taking the clenbuterol hydrochloride, taking compressed nitrogen as a gas source, and crushing by adopting a jet mill. Feeding pressure is 7.0bar, crushing pressure is 6.0bar, crushing is carried out, the obtained salbutamol hydrochloride micro powder is collected, and the salbutamol hydrochloride micro powder is stored under the dry condition. Precisely weighing lactose micropowder of a prescription amount and lactose carrier which is not containing lactose micropowder and sold in the market, sieving with a 60-mesh sieve, mixing, putting into a wet granulator, adjusting the rotation speed to 300 +/-10 rpm, mixing for 3 times, 10min each time, preparing modified lactose containing 20% lactose micropowder, drying and storing. The clenbuterol hydrochloride micro powder and 150.00g of modified lactose containing 20% lactose micro powder are precisely weighed according to the prescription amount, sieved by a 60-mesh sieve, mixed, put into a wet granulator, adjusted to the rotation speed of 250 +/-10 rpm, mixed for 3 times, each time for 10min, collected, dried and stored. The results of aerodynamic measurement showed that the FPF value was 29.1%, and the results of fluidity measurement showed that the contact angle was 27.8 ℃ and the fluidity was good.
Example 5
Prescription:
chuangbuterol hydrochloride 200mg
Magnesium stearate micropowder 0.75g
Lactose 149.25g
The preparation method comprises the following steps: taking the salbutamol hydrochloride, taking compressed nitrogen as a gas source, and crushing by adopting a jet mill. Feeding pressure is 7.0bar, crushing pressure is 6.0bar, crushing is carried out, the obtained salbutamol hydrochloride micro powder is collected, and the salbutamol hydrochloride micro powder is stored under the dry condition. Pulverizing magnesium stearate by the same method, drying and storing to obtain magnesium stearate micropowder. Precisely weighing magnesium stearate micropowder and a commercial lactose carrier without micropowder lactose in a prescription amount, sieving with a 60-mesh sieve, mixing, putting into a wet granulator, adjusting the rotation speed to 300 +/-10 rpm, mixing for 3 times, each time for 10min to prepare modified lactose containing 0.5% of magnesium stearate micropowder, and drying and storing. Precisely weighing the prescription dose of the clenbuterol hydrochloride micro powder and 150g of modified lactose containing 0.5% magnesium stearate micro powder, sieving with a 60-mesh sieve, mixing, putting into a wet granulator, adjusting the rotating speed to 250 +/-10 rpm, mixing for 3 times, each time for 10min, collecting, drying and storing. The results of aerodynamic measurement show that the FPF value is 38.6%, and the results of fluidity test show that the contact angle is 26.4 DEG, and the fluidity is good.
Example 6
Prescription:
chuangbuterol hydrochloride 200mg
Magnesium stearate micropowder 1.5g
Lactose 148.5g
The preparation method comprises the following steps: taking the clenbuterol hydrochloride, taking compressed nitrogen as a gas source, and crushing by adopting a jet mill. Feeding pressure is 7.0bar, crushing pressure is 6.0bar, crushing is carried out, the obtained salbutamol hydrochloride micro powder is collected, and the salbutamol hydrochloride micro powder is stored under the dry condition. Pulverizing magnesium stearate by the same method, drying and storing to obtain magnesium stearate micropowder. Precisely weighing magnesium stearate micropowder in a prescription amount and a commercially available lactose carrier without micropowder lactose, sieving with a 60-mesh sieve, mixing, placing into a wet granulator, adjusting the rotation speed to 300 +/-10 rpm, mixing for 3 times, each time for 10min, preparing modified lactose containing 1% magnesium stearate micropowder, drying and storing. Precisely weighing the prescription dose of the clenbuterol hydrochloride micro powder and 150g of modified lactose containing 1% magnesium stearate micro powder, sieving with a 60-mesh sieve, mixing, putting into a wet granulator, adjusting the rotation speed to 250 +/-10 rpm, mixing for 3 times, each time for 10min, collecting, drying and storing. The aerodynamic measurement result shows that the FPF value is 41.4%, the fluidity test result shows that the contact angle is 25.2 degrees, and the fluidity is good.
Example 7
Prescription:
chuangbuterol hydrochloride 200mg
Magnesium stearate micropowder 2.25g
Lactose 147.75g
The preparation method comprises the following steps: taking the salbutamol hydrochloride, taking compressed nitrogen as a gas source, and crushing by adopting a jet mill. Feeding pressure is 7.0bar, crushing pressure is 6.0bar, crushing is carried out, the Chuangbuterol hydrochloride micro powder is collected, and the storage is carried out under the dry condition. Pulverizing magnesium stearate by the same method, drying and storing to obtain magnesium stearate micropowder. Precisely weighing magnesium stearate micropowder in a prescription amount and a commercially available lactose carrier without micropowder lactose, sieving with a 60-mesh sieve, mixing, placing into a wet granulator, adjusting the rotation speed to 300 +/-10 rpm, mixing for 3 times, each time for 10min, preparing modified lactose containing 1.5% of magnesium stearate micropowder, drying and storing. The clenbuterol hydrochloride micro powder and 150g of modified lactose containing 1.5% magnesium stearate micro powder are precisely weighed according to the prescription amount, screened by a 60-mesh sieve, mixed, put into a wet granulator, adjusted to the rotation speed of 250 +/-10 rpm, mixed for 3 times, each time for 10min, collected, dried and stored. The aerodynamic measurement result shows that the FPF value is 40.7%, the fluidity test result shows that the contact angle is 24.8 degrees, and the fluidity is good.
Example 8
Prescription:
Figure BDA0002846332140000081
the preparation method comprises the following steps: taking the salbutamol hydrochloride, taking compressed nitrogen as a gas source, and crushing by adopting a jet mill. Feeding pressure is 7.0bar, crushing pressure is 6.0bar, crushing is carried out, the Chuangbuterol hydrochloride micro powder is collected, and the storage is carried out under the dry condition. Pulverizing magnesium stearate by the same method, drying and storing to obtain magnesium stearate micropowder. Precisely weighing magnesium stearate micropowder, lactose micropowder and commercial lactose carrier without micropowder lactose according to the formula amount, sieving with a 60-mesh sieve, mixing, putting into a wet granulator, adjusting the rotation speed to 300 +/-10 rpm, mixing for 3 times, each time for 10min, preparing the modified lactose containing 1% of magnesium stearate micropowder and 10% of lactose micropowder, drying and storing. Accurately weighing the prescription dose of the clenbuterol hydrochloride micro powder and 150.00g of modified lactose, sieving by a 60-mesh sieve, mixing, putting into a wet granulator, adjusting the rotation speed to 250 +/-10 rpm, mixing for 3 times, each time for 10min, collecting the product, drying and storing. The aerodynamic measurement result shows that the FPF value is 47.8%, the fluidity test result shows that the contact angle is 26.2 degrees, and the fluidity is good.
Example 9
Prescription:
chuangbuterol 200mg
Magnesium stearate micropowder 1.50g
Lactose 148.50g
The preparation method comprises the following steps: taking the albuterol and the magnesium stearate, roughly mixing according to the proportion of the prescription, and crushing by using a jet mill by using compressed nitrogen as a gas source. The feed pressure was 7.0bar and the comminution pressure was 6.0bar. Collecting the product which is the co-pulverized micro powder of the albuterol and the magnesium stearate, determining the particle size, drying and storing. Precisely weighing the co-ground micro powder of the albuterol and the magnesium stearate in the prescription amount and a commercial lactose carrier without micro powder lactose, sieving by a 60-mesh sieve, mixing, putting into a wet granulator, adjusting the rotation speed to 250 +/-10 rpm, mixing for 3 times, each time for 10min, collecting the product after the mixing is finished, drying and storing. The results of aerodynamic measurement show that the FPF value is 30.5%, and the results of fluidity test show that the contact angle is 27.5 degrees, and the fluidity is good.
Example 10
Prescription:
100mg of Chuangbuterol hydrochloride
Lactose containing 10% lactose micropowder 150.00g
The preparation method comprises the following steps: taking the salbutamol hydrochloride, taking compressed nitrogen as a gas source, and crushing by adopting a jet mill. Feeding pressure is 7.0bar, crushing pressure is 6.0bar, crushing is carried out, the obtained salbutamol hydrochloride micro powder is collected, and drying and storage are carried out. The clenbuterol hydrochloride micro powder and the commercial lactose carrier containing 10% of micro powder lactose are precisely weighed according to the prescription amount, sieved by a 60-mesh sieve, mixed, put into a wet granulator, the rotation speed is adjusted to be 250 +/-10 rpm, the mixing time is 10 min/time, and mixed for 3 times. After the mixing is finished, collecting the product, drying and storing. The aerodynamic measurement result shows that the FPF value is 29.3%, the fluidity test result shows that the contact angle is 28.6 degrees, and the fluidity is good.
Example 11
Prescription:
chuangbuterol hydrochloride 300mg
Lactose containing 10% lactose micropowder 150.00g
The preparation method comprises the following steps: taking the clenbuterol hydrochloride, taking compressed nitrogen as a gas source, and crushing by adopting a jet mill. Feeding pressure is 7.0bar, crushing pressure is 6.0bar, crushing is carried out, the obtained salbutamol hydrochloride micro powder is collected, and drying and storage are carried out. The clenbuterol hydrochloride micro powder with the prescription amount and the commercial lactose carrier containing 10 percent of micro powder lactose are precisely weighed, sieved by a 60-mesh sieve, mixed, put into a wet granulator, the rotating speed is adjusted to be 250 plus or minus 10rpm, the mixing time is 10 min/time, and mixed for 3 times. After the mixing is finished, collecting the product, drying and storing. The results of aerodynamic measurement showed that the FPF value was 32.6%, and the results of fluidity measurement showed that the contact angle was 28.2 °, and the fluidity was good.
Example 12
Prescription:
chuangbuterol hydrochloride 200mg
Leucine micropowder 1.50g
Lactose 148.50g
The preparation method comprises the following steps: taking the clenbuterol hydrochloride, taking compressed nitrogen as a gas source, and crushing by adopting a jet mill. The feed pressure was 7.0bar and the comminution pressure was 6.0bar. Collecting the product which is the clenbuterol hydrochloride micro powder, measuring the particle size, drying and storing. Pulverizing leucine by the same method, drying, and storing. The leucine micro powder and the lactose carrier without micro powder lactose are precisely weighed according to the prescription amount, screened by a 60-mesh sieve, put into a wet granulator, the rotating speed is adjusted to be 300 plus or minus 10rpm, the mixing time is 10 min/time, and the mixture is mixed for 3 times. After mixing, collecting the product which is modified lactose containing 1% leucine micropowder, drying and storing. The clenbuterol hydrochloride micro powder and 150.00g of modified lactose containing 1% leucine micro powder in the prescription amount are precisely weighed, sieved by a 60-mesh sieve, put into a wet granulator, the rotation speed is adjusted to be 250 +/-10 rpm, the mixing time is 10 min/time, and the mixture is mixed for 3 times. After the mixing is finished, collecting the product, drying and storing. The results of aerodynamic measurement show that the FPF value is 29.1%, and the results of fluidity test show that the contact angle is 27.9 DEG, and the fluidity is good.
Example 13
Prescription:
chuangbuterol hydrochloride 200mg
Magnesium stearate micropowder 1.5g
Lactose 148.5g
The preparation method comprises the following steps: taking the clenbuterol hydrochloride, taking compressed nitrogen as a gas source, and crushing by adopting a jet mill. Feeding pressure is 7.0bar, crushing pressure is 6.0bar, crushing is carried out, the obtained salbutamol hydrochloride micro powder is collected, and the salbutamol hydrochloride micro powder is stored under the dry condition. Precisely weighing magnesium stearate and lactose carrier according to the prescription amount, sieving with a 60-mesh sieve, mixing, putting into a wet granulator, adjusting the rotation speed to 300 +/-10 rpm, mixing for 3 times, 10min each time, preparing modified lactose containing 1% of magnesium stearate, drying and storing. The clenbuterol hydrochloride micro powder and 150g of modified lactose containing 1% of magnesium stearate are precisely weighed according to the prescription amount, screened by a 60-mesh sieve, mixed, put into a wet granulator, adjusted to the rotation speed of 250 +/-10 rpm, mixed for 3 times, each time for 10min, collected, dried and stored. The results of aerodynamic measurement showed that the FPF value was 29.6%, and the results of fluidity measurement showed that the contact angle was 25.9 °, and the fluidity was good.
Example 14
Prescription:
Figure BDA0002846332140000101
the preparation method comprises the following steps: taking the clenbuterol hydrochloride, taking compressed nitrogen as a gas source, and crushing by adopting a jet mill. Feeding pressure is 7.0bar, crushing pressure is 6.0bar, crushing is carried out, the Chuangbuterol hydrochloride micro powder is collected, and the storage is carried out under the dry condition. Pulverizing magnesium stearate by the same method, drying and storing to obtain magnesium stearate micropowder. Precisely weighing magnesium stearate micropowder, lactose micropowder and commercial lactose carrier without micropowder lactose according to the formula amount, sieving with a 60-mesh sieve, mixing, putting into a wet granulator, adjusting the rotation speed to 300 +/-10 rpm, mixing for 3 times, each time for 10min, preparing the modified lactose containing 1% of magnesium stearate micropowder and 10% of lactose micropowder, drying and storing. Accurately weighing the prescription dose of the clenbuterol hydrochloride micro powder and 150.00g of modified lactose, sieving by a 60-mesh sieve, mixing, putting into a wet granulator, adjusting the rotation speed to 250 +/-10 rpm, mixing for 3 times, each time for 10min, collecting the product, drying and storing. The results of aerodynamic measurement show that the FPF value is 45.9%, and the results of fluidity test show that the contact angle is 25.4 DEG, and the fluidity is good.
Comparative example
Prescription:
chuangbuterol hydrochloride 200mg
Lactose 150.00g
The preparation method comprises the following steps: taking the salbutamol hydrochloride, taking compressed nitrogen as a gas source, and crushing by adopting a jet mill. Feeding pressure is 7.0bar, crushing pressure is 6.0bar, crushing is carried out, the obtained salbutamol hydrochloride micro powder is collected, and the salbutamol hydrochloride micro powder is stored under the dry condition. The clenbuterol hydrochloride micro powder and lactose with the prescription amount are precisely weighed, and are put into a wet granulator after being sieved by a 60-mesh sieve, the rotating speed is adjusted to be 250 plus or minus 10rpm, the mixing time is 10 min/time, and the mixture is mixed for 3 times. After the mixing is finished, collecting the product, drying and storing. The results of the aerodynamic measurement showed that the FPF value was 17.5% and the results of the flowability measurement showed that the contact angle was 35.3 °.
Test example 1
The particle size of each component in the dry powder inhalation preparation has a significant effect on the properties of the preparation. The particle size of each composition was determined by dry laser diffraction method (neopataxane laser granulometer, germany). Using the ROLOS module, R1/R3 lens, operating mode ref 5s start 1%.
Table 1 shows the results of particle size determination of the raw and auxiliary materials, i.e. the intermediate, wherein after jet milling, the salbutamol or the salbutamol and the surface modifier are subjected to jet milling, spray drying or supercritical fluid technology treatment to form particles with a particle size suitable for pulmonary inhalation administration, so that the particles can be used for further preparation of dry powder inhalation preparations. The particle size of various surface modifier micro powder is equivalent to that of the Chuangbuterol micro powder, which is beneficial to playing the surface modification effect on the lactose carrier.
Test example 2
And (3) determining the content uniformity of the aerosol powder by adopting a high performance liquid chromatography method. After the powder and aerosol mixing is finished, six sampling positions are selected in a wet granulator, about 100mg of samples are removed respectively, the samples are precisely weighed and then put into a 25mL volumetric flask, water is added for dissolving, constant volume shaking is carried out uniformly, and the concentration of the samples is analyzed by a high performance liquid chromatography.
Tables 2 and 3 show the content measurement results of the aerosols of examples 1 and 2 at various time points, respectively, and the content uniformity has no significant difference with different mixing times at the respective mixing speeds.
Test example 3
Due to the physiological structure of the lungs, and the specificity of pulmonary delivery, a powder drug needs to have specific aerodynamic properties in order to be effectively deposited in the lungs. The deposition of the powder in the lung directly affects the therapeutic effect of the drug. According to the regulation of Chinese pharmacopoeia in 2015, the fog drop (particle) distribution of the effective part is used as an index for screening to evaluate the reasonability of process parameters. The invention utilizes a new generation of pharmaceutical impactor (NGI) to determine the aerodynamic behavior of the preparation. And the results are used as the basis for prescription screening.
FIG. 1 shows the results of aerodynamic measurements of drug and lactose carriers in a powder inhalation of salbutamol hydrochloride at 100rpm for different mixing times. The aerodynamic performance of the medicine in the powder inhalation is improved along with the prolonging of the mixing time.
FIG. 2 shows the results of aerodynamic measurements of drug and lactose carriers in a powder inhalation of salbutamol hydrochloride at 250rpm for different mixing times. The deposition of drug particles at each level of the NGI varies with mixing time. The aerodynamic behaviour is best when mixed for more than 30 min.
The aerodynamic performance of the powder spray is improved by adding a surface modifier into the carrier. In the comparative example, the powder spray was prepared using unmodified lactose as a carrier, and aerodynamic properties were measured to compare the use of the modifier.
Figure 3 and table 4 compare the aerodynamic performance of the dry powder aerosol of each example.
Examples 3 and 4, the aerodynamic properties of the powder aerosol were improved by adding 10% and 20% lactose micropowder to the lactose carrier, and the powder aerosol with 20% lactose micropowder content had a higher FPF value. However, since lactose fine powder has a high surface energy and is easily agglomerated, 20% of the fine powder content in the actual production process causes problems of non-uniform content and segregation of the drug from the carrier.
Examples 5,6 and 7 improved the aerodynamic properties of the powder spray by adding 0.5%,1% and 1.5% of fine magnesium stearate powder to the lactose carrier, and the powder spray with a magnesium stearate content of 1% had a higher FPF value.
In examples 8 and 14, 10% lactose fine powder, 1% magnesium stearate fine powder and 20% lactose fine powder are used, and 2% magnesium stearate fine powder is used to modify the lactose carrier at the same time, when the weight ratio of magnesium stearate fine powder to lactose fine powder is: 1:20-1:10, it has better aerodynamic behavior and better favorable deposition of the drug in the lung.
The co-pulverized fine powder of salbutamol and magnesium stearate prepared by the co-pulverization method in example 9 has improved aerodynamic behavior, probably because the drug is co-pulverized with magnesium stearate, the energy of the drug contacting the lactose carrier is changed, and the drug particles are more easily detached from the lactose surface.
In examples 10 and 11, different amounts of salbutamol hydrochloride were added to the formulations, and the FPF increased with increasing amounts of salbutamol hydrochloride.
In example 12, 1% leucine was used to modify lactose and produce a powder aerosol, which improved the aerodynamic properties.
In example 13, the aerodynamic performance of the powder spray is improved by modifying and preparing the powder spray by using 1% of magnesium stearate, but the modification effect is weaker than that of the powder spray prepared by adding 1% of magnesium stearate micropowder in example 6. The micronization treatment of the magnesium stearate is illustrated, which is beneficial to the magnesium stearate to exert the modification effect of the lactose carrier.
Test example 4
The powder repose angle is measured by adopting a fixed funnel method, a funnel is fixed above coordinate paper (the paper is placed on a horizontal table) at a certain height, materials are added from the funnel until the top of a formed stacking cone is just contacted with the bottom of the funnel, the diameter of the cone is measured, and the repose angle is calculated by taking the ratio of the height of the bottom of the funnel to the radius of the cone as a tangent value.
Table 4 shows the fluidity results of the comparative examples and each example. By adding lactose micropowder, magnesium stearate micropowder and leucine micropowder, the flowability of the powder spray is improved, and the flowability is better and better along with the increase of the addition amount.
Test example 5
Drying and storing the raw material medicine and the intermediate, putting the powder to be dried and stored into an aluminum foil bag, adding allochroic silica gel into the aluminum foil bag as a drying agent, sealing, and placing in a dryer containing the allochroic silica gel for room temperature storage.
Test example 6
The powder spray agent is used for accelerating the experiment, and the storage conditions are as follows: storing at 40 deg.C and 75% humidity for 7 days; storing at 40 deg.C and 75% humidity for 14 days; storing at 40 deg.C and 75% humidity for 30 days; storing at 40 deg.C and 75% humidity for 60 days; the temperature is 40 ℃, and the humidity is 75 percent for 90 days.
FIG. 4 and Table 5 show the results of accelerated test measurement of the powder cloud of example 2 with a mixing time of 30 min. The result shows that the FPF value of the salbutamol hydrochloride in the powder inhalation is not obviously reduced, which indicates that the powder inhalation is relatively stable under the conditions of the temperature of 40 ℃ and the humidity of 75 percent.
TABLE 1 particle size of raw and auxiliary materials and intermediates
Figure BDA0002846332140000131
TABLE 2 sample point contents (%)% of Chuanybuterol hydrochloride powder aerosol prepared at 100rpm in example 1
Figure BDA0002846332140000132
Figure BDA0002846332140000141
Table 3 the content (%) of each sample point of the salbutamol hydrochloride powder aerosol was prepared at a mixing speed of 250rpm in example 2.
Figure BDA0002846332140000142
TABLE 4 aerodynamic vs. flowability comparison
Figure BDA0002846332140000143
Table 5 aerodynamic results of accelerated test of salbutamol hydrochloride aerosol powder mixture at 250rpm for 30min in example 2.
Figure BDA0002846332140000144
Figure BDA0002846332140000151
The results show that the aerodynamic behavior of the drug in each example is improved compared to the comparative example by modification of the lactose carrier. After different surface modifiers are added, the FPF value of the salbutamol hydrochloride powder inhalation is improved, preferably the following proportion is selected, and the weight ratio of the lactose micropowder to the lactose is as follows: 1:4- -1:9; the weight ratio of the magnesium stearate micropowder to the lactose is as follows: 1:199- -3:197; the weight ratio of leucine to lactose is: 1:199- -3:197; the weight ratio of the magnesium stearate micropowder, the lactose micropowder and the lactose is as follows: 1:20:378.8-1:10:28.9, more preferably 1:10:89-1:20: 79.

Claims (5)

1. the albuterol inhalation powder inhalation is characterized by comprising active ingredients and a surface modified carrier, wherein the components in percentage by weight are as follows: 0.05 to 0.25 percent of active ingredient and 99.75 to 99.95 percent of surface modified carrier, wherein the active ingredient is the salbutamol or the salbutamol hydrochloride micropowder, the surface modified carrier is the carrier which is subjected to surface modification by a surface modifier, the surface modified carrier is a lactose carrier containing micropowder lactose and micropowder magnesium stearate, and the weight ratio of the micropowder magnesium stearate, the micropowder lactose and the lactose is as follows: 1:10:89-1:20:79; the Chuanbuterol or the Chuanbuterol hydrochloride micro powder is characterized in that: median diameter D 50 Less than 2 microns, 90% of the particle diameter D of the salbutamol micropowder 90 Less than 3 μm; the surface modifier is characterized in that: after micronization, the median diameter D of the surface modifier micropowder 50 Less than 5 μm,90% of the surface modifier micropowder 90 Less than 10 μm;
the preparation method of the albuterol inhalation powder spray comprises the following steps:
(1) Preparing the Chuanbuterol or the Chuanbuterol hydrochloride micro powder;
(2) Preparing a surface modified carrier;
(3) Mixing the clenbuterol or the clenbuterol hydrochloride micro powder with the surface modified carrier;
the clenbuterol or the clenbuterol hydrochloride micro powder in the step (1) is prepared by adopting a jet milling method;
and (3) preparing the surface modified carrier in the step (2), namely performing high-shear mixing treatment on the carrier and the carrier surface modifier or the surface modifier micropowder by adopting a mixing granulator, wherein the high-shear mixing speed is 100-300rpm.
2. The Chuangbuterol powder inhalation of claim 1, which is characterized in that the weight percentages of the Chuangbuterol hydrochloride micro powder, the micro powder magnesium stearate, the micro powder lactose and the lactose are as follows: 1:5:50:445- -1:5:100:395.
3. the Chuangbuterol powder inhalation is characterized by comprising the following components:
chuangbuterol hydrochloride 200mg
Magnesium stearate micropowder 1.5g
Lactose micropowder 15g
Lactose 133.5 g
The preparation method comprises the following steps: taking the salbutamol hydrochloride, taking compressed nitrogen as a gas source, crushing by adopting a jet mill under the feeding pressure of 7.0bar and the crushing pressure of 6.0bar, crushing, collecting salbutamol hydrochloride micro powder, and storing under a dry condition; pulverizing magnesium stearate by the same method, drying and storing to obtain magnesium stearate micropowder; precisely weighing magnesium stearate micropowder, lactose micropowder and commercially available lactose carrier without micropowder lactose in a prescribed amount, sieving with a 60-mesh sieve, mixing, placing into a wet granulator, adjusting the rotation speed to 300 +/-10 rpm, mixing for 3 times, each time for 10min to obtain modified lactose containing 1% of magnesium stearate micropowder and 10% of lactose micropowder, drying and storing; accurately weighing the prescription dose of the clenbuterol hydrochloride micro powder and 150.00g of modified lactose, sieving by a 60-mesh sieve, mixing, putting into a wet granulator, adjusting the rotation speed to 250 +/-10 rpm, mixing for 3 times, each time for 10min, collecting the product, drying and storing.
4. The Chuangbuterol powder inhalation is characterized by comprising the following components:
chuangbuterol hydrochloride 200mg
Magnesium stearate micropowder 1.5g
Lactose micropowder 30g
Lactose 118.5g
The preparation method comprises the following steps: taking the salbutamol hydrochloride, taking compressed nitrogen as a gas source, crushing by adopting a jet mill under the feeding pressure of 7.0bar and the crushing pressure of 6.0bar, crushing, collecting salbutamol hydrochloride micro powder, and storing under a dry condition; pulverizing magnesium stearate by the same method, drying and storing to obtain magnesium stearate micropowder, precisely weighing magnesium stearate micropowder, lactose micropowder and lactose carrier without micropowder lactose in the market according to the formula amount, sieving with a 60-mesh sieve, mixing, placing into a wet granulator, adjusting the rotation speed to 300 +/-10 rpm, mixing for 3 times, each time for 10min, preparing modified lactose containing 1% of magnesium stearate micropowder and 20% of lactose micropowder, drying and storing; accurately weighing the prescription dose of the clenbuterol hydrochloride micro powder and 150.00g of modified lactose, sieving by a 60-mesh sieve, mixing, putting into a wet granulator, adjusting the rotation speed to 250 +/-10 rpm, mixing for 3 times, each time for 10min, collecting the product, drying and storing.
5. Use of the salbutamol inhalation aerosol formulation according to any one of claims 1 to 4 for the manufacture of a medicament for the treatment of asthma or chronic obstructive pulmonary disease.
CN202011510645.1A 2020-12-19 2020-12-19 Chuangbuterol powder inhalation and preparation method thereof Active CN112451509B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202011510645.1A CN112451509B (en) 2020-12-19 2020-12-19 Chuangbuterol powder inhalation and preparation method thereof
PCT/CN2021/106225 WO2022127092A1 (en) 2020-12-19 2021-07-14 Trantinterol dry powder inhaler, preparation method therefor, and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011510645.1A CN112451509B (en) 2020-12-19 2020-12-19 Chuangbuterol powder inhalation and preparation method thereof

Publications (2)

Publication Number Publication Date
CN112451509A CN112451509A (en) 2021-03-09
CN112451509B true CN112451509B (en) 2023-03-07

Family

ID=74803081

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011510645.1A Active CN112451509B (en) 2020-12-19 2020-12-19 Chuangbuterol powder inhalation and preparation method thereof

Country Status (2)

Country Link
CN (1) CN112451509B (en)
WO (1) WO2022127092A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112451509B (en) * 2020-12-19 2023-03-07 沈阳药科大学 Chuangbuterol powder inhalation and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1179097A (en) * 1995-01-31 1998-04-15 协调药物发展有限公司 Carrier particles for use in dry powder inhalers
CN1424909A (en) * 2000-04-17 2003-06-18 维克多瑞有限公司 Formulations for use in inhaler devices
CN1923177A (en) * 2006-09-18 2007-03-07 锦州九泰药业有限责任公司 Chlorhydric acid tranditerol aerosol
CN101106975A (en) * 2004-11-23 2008-01-16 维克特拉有限公司 Dry powder inhaler formulations comprising surface-modified particles with anti-adherent additives
CN101433541A (en) * 2008-12-19 2009-05-20 沈阳药科大学 Pharmaceutical composition containing beta2 agonists and steroids, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101032484B (en) * 2007-04-02 2010-05-26 南京卡文迪许生物工程技术有限公司 Capsule type tiotropium bromide inhalation powder
CN101342155B (en) * 2007-07-11 2012-01-04 天津帝士力投资控股集团有限公司 (R,R)-formoterol inhalation dust cloud agent and preparation method thereof
CN112451509B (en) * 2020-12-19 2023-03-07 沈阳药科大学 Chuangbuterol powder inhalation and preparation method thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1179097A (en) * 1995-01-31 1998-04-15 协调药物发展有限公司 Carrier particles for use in dry powder inhalers
CN1424909A (en) * 2000-04-17 2003-06-18 维克多瑞有限公司 Formulations for use in inhaler devices
CN101106975A (en) * 2004-11-23 2008-01-16 维克特拉有限公司 Dry powder inhaler formulations comprising surface-modified particles with anti-adherent additives
CN1923177A (en) * 2006-09-18 2007-03-07 锦州九泰药业有限责任公司 Chlorhydric acid tranditerol aerosol
CN101433541A (en) * 2008-12-19 2009-05-20 沈阳药科大学 Pharmaceutical composition containing beta2 agonists and steroids, and uses thereof

Also Published As

Publication number Publication date
CN112451509A (en) 2021-03-09
WO2022127092A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
US20220296559A1 (en) Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
KR101730684B1 (en) Process for preparing carrier particles for dry powders for inhalation
US7022311B1 (en) Powdery inhalational preparations and process for producing the same
US8586093B2 (en) Pulmonary delivery for levodopa
EP1734938B1 (en) Insulin highly respirable microparticles
MX2014001345A (en) Method and formulation for inhalation.
TW201018468A (en) Inhalable particles comprising tiotropium
CN112451509B (en) Chuangbuterol powder inhalation and preparation method thereof
CN101342155A (en) (R,R)-formoterol inhalation dust cloud agent and preparation method thereof
TWI602566B (en) Formulation, method and apparatus
KR102462058B1 (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
ZA200406911B (en) Powder formulations suitable for inhalation
CN106727348A (en) Low-density carrier granular of moistureproof moisture-resistant and its preparation method and application
Rhein et al. Parteck M DPI-a novel mannitol as carrier in dry powder inhalation formulation
JP2007502791A (en) CGRP antagonist 1- [N2- [3,5-dibromo-N-[[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl ] -L-lysyl] -4- (4-pyridinyl) -piperazine
CN112933047A (en) Preparation method of ultrafine pulverized salmeterol ticasone
KR20200011133A (en) Pharmaceutical formulation containing of bosentan
CN107205958A (en) pharmaceutical composition comprising formoterol and budesonide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant